a 25 kDa recombinant, humanized, single-chain antibody that binds to human C5 with a very high affinity & thereby blocks C5 cleavage by C5 convertases; for treatment of patients undergoing coronary artery bypass graft surgery with cardiopulmonary bypass
Also Known As:
Networked: 62 relevant articles (1 outcomes, 44 trials/studies)

Relationship Network

Bio-Agent Context: Research Results


1. Granger, Christopher B: 39 articles (11/2013 - 09/2003)
2. Armstrong, Paul W: 38 articles (11/2013 - 09/2003)
3. Todaro, Thomas G: 15 articles (07/2011 - 09/2003)
4. Mahaffey, Kenneth W: 13 articles (11/2013 - 09/2003)
5. Westerhout, Cynthia M: 12 articles (02/2013 - 05/2008)
6. Van de Werf, Frans: 12 articles (07/2012 - 03/2005)
7. Patel, Manesh R: 11 articles (11/2013 - 03/2005)
8. Fu, Yuling: 10 articles (02/2013 - 12/2007)
9. Hochman, Judith S: 9 articles (11/2013 - 09/2003)
10. Lopes, Renato D: 9 articles (11/2013 - 07/2010)

Related Diseases

1. Myocardial Infarction
2. Inflammation
10/01/2005 - "Prognostic significance of blood markers of inflammation in patients with ST-segment elevation myocardial infarction undergoing primary angioplasty and effects of pexelizumab, a C5 inhibitor: a substudy of the COMMA trial."
06/01/2008 - "Pexelizumab is an Alexion-engineered monoclonal antibody fragment designed to inhibit complement-mediated tissue damage associated with reperfusion injury and inflammation that occurs during open heart surgery. "
02/01/2006 - "These interventions include the C1 esterase inhibitor, which may be consumed in some inflammatory states resulting in the loss of one of the mechanisms inhibiting activation of the classical and lectin pathways; TP10, a recombinant protein of the soluble complement receptor type 1 (sCR1) which inhibits the C3 and C5 convertases of the common pathway by binding C3b and C4b; a truncated version of the soluble complement receptor type 1 CRI lacking the C4b binding site which selectively inhibits the alternative pathway; and pexelizumab, a monoclonal antibody selectively blocking C5 to prevent the activation of the terminal pathway that is involved in excessive inflammation and autoimmune responses."
07/01/2012 - "The blockage of both C5a and terminal complement in cell culture, but of C5a only in vivo with minimal effects on inflammation and risk biomarkers, supports the hypothesis that late administration of pexelizumab after the ischemia/reperfusion insult precluded adequate myocardial protection, resulting in a negative trial."
07/01/2012 - "A panel of terminal complement complex proteins and fragments and biomarkers of inflammation, apoptosis, and high-risk features were assessed in serum obtained before and 24 hours after administration of placebo or pexelizumab and primary percutaneous coronary intervention (n = 356) and in human umbilical vein endothelial cell cultures coincubated with serum (n = 45). "
3. Ischemia
4. Infarction
5. Shock

Related Drugs and Biologics

1. Complement System Proteins (Complement)
2. Complement C5 (Complement 5)
3. Biological Markers (Surrogate Marker)
4. Sodium
5. gefitinib (Iressa)
6. Insulin (Novolin)
7. peginterferon alfa-2a (Pegasys)
8. duloxetine (Cymbalta)
9. lapatinib (GW572016)
10. efalizumab

Related Therapies and Procedures

1. Coronary Artery Bypass (Coronary Artery Bypass Surgery)
2. Transplants (Transplant)
3. Angioplasty (Angioplasty, Transluminal)
4. Cardiopulmonary Bypass (Heart-Lung Bypass)
5. Stents